Accumulating data have shown the involvement of microRNAs in cancerous processes as either oncogenes or tumor suppressor genes. Here, we established miR-30a as a tumor suppressor gene in breast cancer development and metastasis. Ectopic expression of miR-30a in breast cancer cell lines resulted in the suppression of cell growth and metastasis in vitro. Consistently, the xenograft mouse model also unveiled the suppressive effects of miR-30a on tumor growth and distal pulmonary metastasis. With dual luciferase reporter assay, we revealed that miR-30a could bind to the 3 0 -untranslated region of metadherin (MTDH) gene, thus exerting inhibitory effect on MTDH. Furthermore, we demonstrated that silence of MTDH could recapitulate the effects of miR-30a overexpression, while overexpression of MTDH could partially abrogate miR-30a-mediated suppression. Of significance, expression level of miR-30a was found to be significantly lower in primary breast cancer tissues than in the paired normal tissues. Further evaluation verified that miR-30a was negatively correlated with the extent of lymph node and lung metastasis in patients with breast cancer. Taken together, our findings indicated miR-30a inhibits breast cancer proliferation and metastasis by directly targeting MTDH, and miR-30a can serve as a prognostic marker for breast cancer. Manipulation of miR-30a may provide a promising therapeutic strategy for breast cancer treatment.
INTRODUCTION
Based on the GLOBOCAN worldwide, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008. 1 In contrast to well-confined primary tumors, metastatic disease is always intractable because of its oftentimes surgically inoperable nature and the resistance of disseminated tumor cells to existing therapeutic agents. 2 Indeed, it is not the primary tumors, but the distant metastases are responsible for as much as 90% of cancer-associated mortality. 3 These clinical realities apply to a variety of cancer types including breast cancer, which alone is expected to account for one quarter of all new cancer cases among women worldwide. 4 Despite much advancement in knowledge from more than a century of research, metastasis remains one of the most enigmatic aspects of the disease 5 and the molecular pathways underlying each step are still obscure. Elucidation of the precise molecular circuitry that governs the metastasis process is critical for the reduction of mortality by breast cancer.
Recently, with the latest deciphering of involvement of microRNAs (miRNAs) in numerous biological processes there are new hopes that the above scenario will be rapidly changed. 6 The small (19-25 nucleotides) , non-coding RNAs can modulate the expression of their cognate target genes by binding to the 3 0 -untranslated region (UTR) of target mRNAs, resulting in either translational inhibition or mRNA cleavage. 7, 8 Bioinformatic predictions reveal that miRNAs regulate more than 30% of the protein-coding genes. 9 Accumulating data have pointed to a central regulatory role for miRNAs in the initiation and development of breast cancer. Downregulated miRNAs in breast cancer cells could function as tumor suppressors by negatively regulating oncogenes, 10, 11 alternatively overexpressed miRNAs could function as oncogenes by repressing tumor suppressor genes. 12 The dysregulation of miRNA expression appears to be a general trait of metastatic breast cancer. 13 MiRNA-30a has attracted much attention due to its important role in various biological and pathological process, including development, 14 differentiation, senescence, 15 apoptosis 16 and autophage. 17, 18 However, whether miR-30a is involved in the progression of breast cancer and the underlying mechanism remains poorly understood. In the present study, we showed that miR-30a was associated with breast cancer development and progression by directly targeting metadherin (MTDH), suggesting a tumor suppressor role of miR-30a in breast cancer. Our findings suggested that the restoration of miR-30a represents a promising therapeutic strategy for breast cancer treatment.
RESULTS

Stable miR-30a overexpression suppressed cell proliferation and colonigenic ability in vitro
To generate stable cells overexpressing miR-30a, we examined the expression of miR-30a in a series of breast cancer cell lines ( Figure 1a ). As parental MCF-7, MDA-MB-231 and T47D cells expressed much lower miR-30a, we decided to overexpress miR-30a in these three cell lines. In order to achieve stable overexpression, we constructed a plasmid with a 500-bp fragment insertion, which contained pre-miR-30a sequence (Figure 1b) . Quantitative real-time PCR demonstrated that pMSCV miR-30a vector could overexpress miR-30a efficiently in the transfected MDA-MB-231, MCF-7 and T47D cells (Figure 1c) .
In order to test the generality of the impact of miR-30a regulation in cell growth, we applied cell viability assay. As a result, cell viability assay showed that the introduction of miR-30a overexpressing vector was able to suppress cell proliferation significantly in vitro (Figures 1d-f) . To further investigate the role of miR-30a in breast cancer, we adopted the colonigenic assay to evaluate its oncogenic potential. As shown in Figures 1g-i, cells transfected with pMSCV miR-30a vector exhibited significantly reduced cologinic ability in all three cell lines. Interestingly, we found MDA-MB-231 cells transfected with pMSCV miR-30a vector were inclined to build more confined colonies than the cells transfected with control vector (Supplementary Figure S1a) , which was consistent with the observation that miR-30a conferred a nonaggressive appearance to breast cancer cells (Supplementary Figure S1b) .
Ectopic expression of miR-30a suppressed cell migration and invasion in vitro Due to the obsevation that the cells overexpressing miR-30a represented the non-aggressive appearence, we hypothesized that miR-30a could suppress the invasive behaviors of breast cancer cells. Transwell assay was employed to detect the migration and invasion of breast cancer cells after miR-30a manipulation. To eliminate the potential cofounding effect of cell proliferation on cell migration and invasion, the transwell experiments were also conducted in the presence of mitomycin C to arrest cell proliferation afterwards.
As shown in Figures 2a-c, miR-30a could potentially suppress migration and invasion of MDA-MB-231, MCF-7 as well as T47D cells in the absence of mitomycin C. Quantitative analysis showed the statistical significance obtained by student's t-test (Figures 2d-f) . Next, control and miR-30a-transfected cells pretreated with mitomycin C were applied for the transwell assays. We found that although mitomycin C eliminated the contribution of cell proliferation, the potent suppressive role of miR-30a in cell migraiton and invasion could still be observed. Subsequent experiments were conducted without mitomycin C treatment.
Then, the wound-healing assay was applied to confirm the inhibitory effect of miR-30a on breast cancer cell migration, and the results were shown in Supplementary Figure S2 . All these observations demonstrated that ectopic expression of miR-30a could impair the migration and invasion of breast cancer cell significantly.
MiR-30a suppressed tumorigenesis and metastasis in a xenograft model To further explore the relationship between miR-30a and tumorigenesis in vivo, the xenograft model of human breast cancer cells in nude mice was adopted. We chose MDA-MB-231 cells, because it is a highly tumorigenic and metastatic cell line compared with the other two cell lines. Briefly, MDA-MB-231 cells overexpressed or not for miR-30a were injected subcutaneously into each flank of nude mice. After cells were injected, tumor volume was monitored every 4 days and the growth curves of tumors were plotted accordingly. Finally, all mice were killed to harvest the xenograft. It is obvious that the tumor volume and weight from the miR-30a overexpression group was reduced significantly when compared with the control group (Figures 3a-c) . Moreover, the control group exhibited evidently faster growth rate (Po0.01, Figure 3d ).
Next, we studied the effect of miR-30a on tumor metastasis in vivo. MDA-MB-231 cells stably overexpressing miR-30a or not was transplanted into the nude mice via tail vein injection. After 2 weeks, mice were anesthetized and their lungs were dissected and hematoxylin and eosin staining was performed to evaluate tissue morphology (Figure 3e ). Two out of seven mice transplanted with MDA-MB-231 miR-30a cells had small pulmonary metastatic nodules, while all seven mice in the control group ended up with heavy lung metastasis. Moreover, the counts of pulmonary metastatic nodules exhibited significant reduction in the miR30a overexpression group, suggesting a crucial role of miR-30a as the metastatic suppressor in vivo (Figure 3f ).
Dual luciferase assay showed MTDH was the direct target of miR-30a To further explore the molecular mechanism of miR-30a-mediated pathological functions, we used bioinformatic strategy to identify the candidate targets of miR-30a. We first analyzed the target genes shared by three widely used bioinformatics algorithms: TargetScan, 19 PicTar 20 and miRanda. 21 Then, we adopted the miR-Ontology Database 22 to identify the potential targets within cancer-associated classification, and finally 17 genes (Supplementary Table S1 ) were successfully identified. Among these 17 genes, MTDH was of particular interest as our previous studies have revealed its crucial role in the metastatic cascade. 23 As shown in Figure 4a , the miRNA: mRNA alignment analysis showed that the 3 0 -UTR of MTDH contains two putative binding sites for miR-30a located at 287-295 nt and 1569-1577 nt. In addition, the homology test showed that the binding sites of miR30a are evolutionarily conserved in a variety of vertebral species (Figure 4b ). In accordance with the above analyses, we observed a clear reduction of MTDH expression in all the three breast cancer cell lines that were stably transfected with miR-30a ( Figure 4c ). To validate direct targeting of MTDH by miR-30a, we cloned each of the putative binding sites of miR-30a individually into the pmiRGLO vector. As indicated in Figure 4d , two corresponding mutant vectors with several nucleotide substitutions in the core binding sites were also constructed. Apparently, co-transfection of HEK293T cells with miR-30a mimics and the pmiRGLO-wt1 3 0 -UTR vector showed a significantly decreased luciferase activity than those cells transfected with the negative control ( Figure 4e ). Similar result was also obtained from the HEK293T cells transfected with pmiRGLO-wt2 3 0 -UTR vector, indicating both of the putative binding sites were functional. Consistent with the results, we observed the same effect in both MDA-MB-231 cells and T47D cells stably transfected with pMSCV miR-30a vector or the control vector (Figures 4f and g ).
MiR-30a inhibited breast cancer cell migration and invasion by targeting MTDH As miR-30a inhibits breast cancer cell migration and invasion and suppresses MTDH protein expression, we are interested in exploring whether miR-30a-mediated metastatic suppression is Furthermore, we attempted to test whether restoration of MTDH could reverse the miR-30a-mediated inhibition of metastatic ability in breast cancer cells. The 'rescue' experiments showed overexpression of MTDH using a cDNA that lacked the 3 0 -UTR containing the miR-30a-binding sites could partially abrogated miR-30a-mediated suppression of migration and invasion in MCF-7 cells (Figures 5d-f ). These results reinforce the idea that MTDH is a direct and functional target of miR-30a.
MiR-30a was negatively correlated with MTDH in cell lines and clinical samples and could function as a tumor suppressor in clinical breast cancer To further validate the idea that miR-30a suppressed the metastasis through targeting MTDH, the expression level of miR-30a and MTDH were detected in a variety of breast cancer cell lines. As indicated in Figure 6a , there existed an inverse correlation between the expression level of miR-30a and MTDH in breast cancer cell lines. The cells with the relatively high endogenous miR-30a expression level exhibited low levels of MTDH as determined by quantitative real-time PCR, and vice versa. Afterwards, the clinical relevance of the above findings was evaluated. We measured the expression of miR-30a and MTDH in a cohort of breast cancer samples and the relative expression level of MTDH was plotted against that of miR-30a in each sample. A moderate negative correlation of MTDH with miR-30a (r ¼ À 0.268, P ¼ 0.023) was observed (Supplementary Figure S3) . These data indicated that miR-30a reduction might be attributed to the overexpression of MTDH in metastatic breast cancer.
To explore the possible role of miR-30a in breast tumorigenesis, we compared the expression levels between breast tumor tissue and paired normal tissue with quantitative real-time PCR. The results showed the expression of miR-30a was downregulated in 21 out of 28 tumor tissue compared with the paired normal tissues (Student's t-test, Po0.001, Figure 6b ). Furthermore, clinicopathological analysis revealed that downregulation of miR-30a was significantly associated with lymph node metastasis (Student's t-test, P ¼ 0.002, Table 1 ). The expression of miR-30a in patients without lymph node metastasis was significantly higher than those patients who had at least one positive lymph node (Figure 6c ). We then investigated whether decreased miR-30a level was associated with an unfavorable outcome in breast cancer patients. Consistently, we detected much lower level of miR-30a in the primary tumor tissue from patients who developed lung metastasis during the follow-up (P ¼ 0.0086, Figure 6d ), suggesting that aberrant regulation of miR-30a might contribute to breast cancer lung metastasis. Thus, our results indicate that miR-30a may serve as a prognostic marker in breast cancer.
DISCUSSION
Accumulating studies have reported that miRNAs are abrretably expressed in many types of human cancers; 24 therefore, better understanding of the gene networks orchestrated by these miRNAs may help exploit the full potential of miRNAs in regards to cancer treatment and therapeutics. MiR-30a has been found to be one of the miRNAs that are downregulated in various types of solid tumor, including colon cancer, 25 prostate cancer, 26 lung cancer 27 and the liver cancer. 28 An elegant study by Cheng et al.
29
has identified that miR-30a are among the significantly downregulated miRNAs in the primary tumor of patients with metastatic cancer than in those with no metastasis, implying a putative function of miR-30a in cancer and potentially metastasis. However, the tumor suppressive role of miR-30a is till poorly understood. In the present study, we reported for the first time that miR-30a had an important role in the suppression of migration and invasion via targeting MTDH gene both in vitro and in vivo.
Chromosomal imbalances including amplifications, deletions or epigenetic alterations occur frequently in cancer development and progression. 30 MiR-30a is mapped to 6q13, which has been reported to be a genomic fragile region due to loss of heterozygosity in breast cancer. 31, 32 In accordance with our observations, miR-30a is decreased in primary breast tumor with metastasis, which could be attributed to the loss of heterozygosity at chromosome 6q13 in aggressive breast cancer. Further exploring the mechanisms by which miR-30a was aberrantly downregulated will deepen our understanding of the metastatic cascade in breast cancer.
On the basis of databases for miRNA target prediction, many miR-30a targets were common targets to other members of the miR-30 family as they share the same seed sequence. 33 To verify this, we examined the influence of all the members of miR-30 family on the translational regulation of MTDH. In accordance with the above statement, our results showed that all the miR-30a family members could downregulate MTDH to different degrees (Supplementary Figure S4) . However, no significant additive effects were detected when we tested the effect of introducing the whole family members simutaneously (data not shown). This is not surprising because they share the same seed region and, thus, likely operate through common targets.
The importance of different miR-30 family members has been highlighted in several contexts. It has been reported that the five miRNAs performed differently although they share a highly conserved sequence except one or two nucleotides. 33 Previous results demonstrated the oncogenic role of miR-30b/d in melanoma cells by indicating that miR-30b/d could enhance the invasive capacity of melanoma cells in vitro and increases their metastatic potential in vivo. 34 Curiously, miR-30e, which shares a seed region with miR-30b/d but is located in a separate genomic location, has shown an anti-metastatic role in breast cancer. 35 Consistent with the function of miR-30e, Ouzounova et al. 33 recently found that miR-30a could downregulate the non-attachment growth of breast cancer cells, which was considered as one characterization of breast tumor-initiating MiR-30a targets metadherin in breast cancer N Zhang et al cells. Additionally, the miR-30c expression has been suggested as an independent predictor for clinical benefit of tamoxifen therapy in patients with advanced breast cancer. 36 These incompatible observations underscore the targets-dependence of miRNA functions in cancer; alternatively different family members may perform in a cell type-specific pattern. Considering the importance of the miR-30 family in predicting progression and outcome of breast cancer, further investigations are required to extend this approach from a single miRNA to multiple miRNAs to understand the cross-talk among miR-30 members in etiological pathways.
According to previous reports, various strategies can be applied to identify the putative targets of miRNAs. In the present study, we adopted three widely acknowledged bioinformatic algorithms to search for the potential targets. More importantly, we used the miR-ontology database to narrow down the potential targets within cancer-associated classification, and finally identify MTDH as a novel functional target of miR-30a. The MTDH gene, mapped to chromosome region 8q22, is frequently amplified in primary tumors and its expression level is always associated with the progression and/or worse prognosis of various types of cancers. [37] [38] [39] [40] [41] As a potent mediator in the development of malignancies, MTDH participates in multiple pathological steps. Remarkably, MTDH is more famous as a mediator of broad-spectrum chemoresistance. To be specific, it has been indicated that knock down of MTDH could sensitize cancer cells to cell death induced by doxorubicin, cisplatin, tamoxifen and TRAIL. [42] [43] [44] Previously, others and we have found most of the tumors with 8q22 gain express abundant level of MTDH protein, while there is a substantial fraction (12%) of samples with normal DNA copy numbers also expressing a high level of MTDH protein. 23, 45 Thus, we speculate the downregulation of some miRNAs might account for the overexpression of MTDH in breast cancer as an alternative mechanism distinct from 8q22 gain. In addition to miR-30a, several researchers have verified that miR-375 could suppress cell invasion and metastasis via directly targeting MTDH, 46, 47 and re-expression of miR-375 was sufficient to sensitize tamoxifen resistant cells to tamoxifen and partly reversed epithelial-mesenchymal transition in breast cancer cells. 48 Consistent with these findings, we verified the effects of miR-375 on cell migration and invasion via downregulation of MTDH (Supplementary Figure S5) , suggesting that miR-375 and miR-30a may concurrently regulate the expression level of MTDH. Nevertheless, more research is needed to understand how these two miRNAs coordinately depressing MTDH, and one plausible schema remains that miR-375 and miR-30a could cooperate with each other to exert their functions.
It is worth noting that a single miRNA can influence the expression of various transcripts that have important roles in cancer development and progression. 49 Previous studies have reported several functional targets of miR-30a in cancer-related processes, including beclin-1 in autophage, 17, 18 B-Myb in cell senescence 15 and snail in epithelial-mesenchymal transition process. 50 Recently, Cheng et al. 29 have reported the role of miR-30a in regulation of epithelial-mesenchymal transition by downmodulating vimentin expression, which is in accordance with our observation that the cells overexpressed miR-30a take on the 'epithelial' shape. In the present study, we showed that the suppressive effect of miR-30a on MTDH expression could lead to the decreased migration and invasion in breast cancer cells. Furthermore, a significant increase in luciferase activity was observed in the cells transfected with the mutated 3 0 -UTR of MTDH (Figures 4e-g ), which confirmed the direct binding of miR30a to MTDH gene. However, knock down of miR-30a in the cells in which MTDH was already knocked down led to about 70% drop in MTDH expression compared with MTDH knocked down alone (Figure 5a ; lane 2 versus 4), while the inhibitory effect of migration and invasion were only half of that (Figure 5c ). The possible interpretation could be that MTDH and miR-30a act in the same pathway but that the phenotype caused by miR-30a cannot solely be explained by downregulation of MTDH, other target(s) regulated by miR-30 may also contribute to this phenotype.
As for the clinical correlation between miR-30a and breast cancer progression, we demonstrated that miR-30a is highly downregulated in the patients with lymph node or lung metastasis. However, we failed to identify miR-30a as a prognostic factor for lung metastasis, which was inconsistent with the previous study. 29 A plausible explanation about this contradiction is that the follow-up time is too short to get a significant prognostic result although sensoring was applied in the statistical analysis. In addition, the small size of the cohort could also account for the inconsistent finding. Thus, larger corhort with longer follow-up time needs to be further investigated.
Regardless, our results demonstrate that miR-30a is clearly downregulated in the groups with lymph node and lung metastasis, suggesting its anti-metastatic role in breast cancer. Moreover, we found the association of miR-30a was more significant with lung metastasis (P ¼ 0.0086) than metastasis in general (P ¼ 0.013), indicating miR-30a was more relavant to lung metastasis. This observation was in accordance with the previous report that MTDH, the target gene of miR-30a, is a cell surface protein in breast tumors that mediates lung metastasis. One-way ANOVA test. The tumor was scored positive for ER and PR when X10% of the tumor cells on the slide irrespective of the staining intensity. HER-2 was evaluated according to the DAKO score with strong complete membranous staining observed in X30% of tumor cells (DAKO score 3 þ ) was defined as HER-2 positive.
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In conclusion, our study demonstrates, for the first time, the role of miR-30a in suppressing breast cancer migration and invasion mediated by MTDH, an effective oncogene in tumorigenesis and metastasis. Moreover, miR-30a expression inversely correlates with lymph node or lung metastasis in breast cancer patients, supporting the notion that loss of miR-30a consequences in gaining expression of oncogene MTDH, which in turn favors breast cancer metastasis. Given the crucial role of miR-30a in breast cancer metastasis, we hopefully speculate that manipulation of miR-30a may represent a promising therapeutic strategy for breast cancer treatment in the near future.
MATERIALS AND METHODS
Cell lines and culture conditions
Breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-468 and HEK293T were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA), and were routinely cultured in DMEM/high glucose medium (GIBCO Laboratories, Grand Island, NY, USA) supplemented with 10% FBS (Haoyang biological manufacture, Tianjin, China), 100 U/ml penicillin and 100 mg/ml streptomycin. SK-BR-3 and ZR-75-1 cells were cultured in RPMI 1640 (GIBCO) supplemented with 10% FBS and antibiotics. T47D cells were maintained in complete RPMI 1640 with 10 mg/ml bovine insulin (SigmaAldrich, St Louis, MO, USA). The retroviral transient producer cell line H29 was maintained in complete DMEM medium supplemented with tetracycline (1 mg/ml). All the cells were cultured at 37 1C and 5% CO 2 .
Plasmid construction and transfection
A 500-bp fragment containing pre-miR-30a was cloned into the pMSCV puro vector to generate overexpression of miR-30a in cells. Then, the pMSCV miR-30a vector and the control vector were transfected into the H29 transient retroviral producer cell line. After transfection of H29 cells, the tetracycline block was removed to allow for retroviral vector production. The pMSCV retrovirus-containing medium was collected for two consecutive days and stored at À 80 1C. The overexpression and knockdown vector for MTDH gene were constructed as described previously. 23, 45 For MTDH overexpression, the cDNA of MTDH was cloned into the multiple cloning site of the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). For MTDH knock down, the 60-nt oligonucleotides were annealed and inserted into the pSUPER.retro.puro vector (OligoEngine, Seattle, WA, USA) to generate MTDH short hairpin RNA. Primers for plasmid construction are shown in Supplementary Table 2 . Transfection was performed with lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.
Quantitative real-time PCR analysis
Total RNA was extracted from cultured cells with TRIzol reagents (Invitrogen) according to the manufacturer's protocol. Total RNA was reverse transcribed to cDNA by using Prime Script RT reagent Kit (Takara, Dalian, China). One microgram of total RNA was reverse transcribed to total miRNA with One Step Prime Script miRNA cDNA Synthesis Kit (Takara). Real-time PCR was performed with the SYBR green Premix Ex Taq II (Takara) with Applied Biosystems Step One Plus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Both GAPDH and ACTB were used as the endogenous control for detection of mRNA expression level, while U6 and total RNA were used as endogenous control for miRNA expression analysis. Relative quantification analysis was performed using the comparative C (T) (2( À DDCT)) method. Primer information used in the study can be found in Supplementary Table S2 .
Western blot analysis
Western blot analysis was performed as described previously. 52 Cells were collected and lysed with radio immunoprecipitation assay buffer (PBS, 1% NP40, 0.1% SDS, 5 mM ethylenediaminetetraacetic acid, 0.5% sodium deoxycholate, 1 mM sodium orthovanadate) with protease inhibitors. Equal amounts of proteins was resolved on SDS-PAGE gels and then transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). After blocking with 5% non-fat milk, the membrane was incubated overnight at 4 1C with the primary antibody (Immuno-Way, Newark, DE, USA) and then with horseradish peroxydase-coupled secondary antibody. Signal was detected with enhanced chemiluminescence.
Cell Proliferation and clonogenic assay Cell proliferation was assessed by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Breast cancer cells were plated in 96-well plates (2 Â 10 3 per well). After incubation at 37 1C for 1-5 days, 20 ml of MTT (5 mg/ml in PBS) was added to each well, and cells were incubated for another 4 h at 37 1C. The supernatants were carefully removed and 100 ml of dimethyl sulfoxide was added to each well. The plates were gently shaken and the absorbance values were measured at 550 nm with a Microplate Reader (Thermo Fisher Scientific, Rockford, IL, USA). To determine clonogenic ability, cells were allowed to grow for 14 days to form colonies, which were then stained with crystal violet (2%, w/v; Sigma, St Louis, MO, USA).
Migration and invasion assay
Migration and invasion assays were performed as described previously 52 using Transwell system (24-well, 8 mm pore size with polycarbonate membrane; Corning Costar, Lowell, MA, USA). The invasion assay was performed in the same way as the migration assay except that the membrane was coated with Matrigel (BD Biosciences, SanJose, CA, USA). Briefly, The polycarbonate membranes were coated with 40 ml matrigel at 37 1C for 2 h to form a reconstituted basement membrane. Seven hundred microlitres of the medium with 20% FBS was added to the lower well of each chamber and 1 Â 10 5 of cells resuspended in the serum-free medium were added to the upper inserts. The total number of cells adhering to the lower surface of the membrane was acquired in six representative fields. Wound-healing assay was also done to assess cell migration. Cells were grown in complete medium to a confluent monolayer and were scraped by 200-ml pipette tips to create an artificial wound.
In vivo tumorigenesis and metastasis assay
The in vivo tumorigenesis and metastasis assay was performed as described previously. 23 Briefly, MDA-MB-231 vector and MDA-MB-231 miR-30a cells (1 Â 10 7 cells in 100 ml of PBS:Matrigel (1:3, v/v)) were injected subcutaneously into each flank of 4-5 weeks-old BALB/c nu/nu female mice (seven mice per group). Tumor growth rate was monitored by measuring tumor diameters every 4 days and the tumor growth curve was recorded accordingly. Both maximum (L) and minimum (W) length of the tumor were measured using a slide caliper, and the tumor volume was calculated as ½LW 2 . When mice were killed, tumors were collected and weighed. To produce experimental lung metastasis, 5 Â 10 5 cells were injected into the lateral tail veins of 4-5 weeks-old BALB/c nu/nu female mice (seven mice per group). After 2 weeks, all the mice were killed under anesthesia. The lungs were collected and fixed in 10% formalin. For tissue morphology evaluation, hematoxylin and eosin staining was performed on sections from embedded samples. All animal experiments were performed with the approval of Shandong University Animal Care and Use Committee.
Dual luciferase reporter assay The 3 0 -UTR of MTDH containing two putative miR-30a-binding sites was amplified and cloned into pmirGLO vector separately (Promega, Madison, WI, USA). Two miR-30a complementary sites with the sequence UGUUUACA in MTDH 3 0 -UTR were mutated singly to remove complementarity to miR-30a as described previously. 53 Cells were cultured in 96-well plates and co-transfected with 100 ng of wide-type or mutated MTDH 3 0 -UTR constructs, or 50 mM of negative control or miR-30a mimics. Luciferase activity was measured with the dual luciferase reporter assay system (Promega).
Patients and tissue samples
The infiltrating carcinoma and the adjacent normal tissue were collected from January 2004 to December 2011 in Qilu hospital at the time of surgery and immediately stored in À 80 1C until use. A total of 96 patients were involved in our study, and among them 28 have matched normal and tumor tissues, which were applied to analyze the ratio of miR-30a expression in normal to tumor lesion. For the distant metastasis, 12 patients had lung metastasis, 2 had bone metastasis and 1 had brain metastasis. The median follow-up is 43 months. None of the patients had received radiotherapy or chemotherapy before surgery. After surgery, 11 patients received radiation and chemotherapy, while 74 patients received chemotherapy alone. For all participants in this study, written informed consent was obtained as delineated by the protocol that was approved by the Ethical Committee of Shandong University.
Statistical analysis
The software SPSS V18.0 was used for statistical analysis. Student's t-test and one-way analysis of variance analysis were used to determine the significance of two groups and multiple groups, respectively. Spearman's correlation was used to identify the correlation between miR-30a expression and MTDH expression. All error bars represent the s.e. of three experiments. Differences with Po0.05 were considered significant.
